Actively Recruiting
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
Led by Cedars-Sinai Medical Center · Updated on 2025-11-10
60
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are: Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside to matched placebos (look-alike substances that contain no drug) to see if these supplements treat symptoms or lung function in people with IPF. Participants will: Take drug these supplements twice a day for 24 weeks. Complete pulmonary function testing and six minute walk tests with their own pulmonologists every 12 weeks. Complete a high resolution CT scan at the start and end of the study. Complete video study visits with the research team every 4 weeks. Complete surveys about their symptoms and the number of times they take the medication.
CONDITIONS
Official Title
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent form
- Willingness to comply with all study procedures and be available for the study duration
- Under active treatment for idiopathic pulmonary fibrosis by a local pulmonologist
- Age over 50 years
- Confirmed diagnosis of idiopathic pulmonary fibrosis based on latest clinical guidelines
- High-resolution CT scan completed within 6 months prior to consent showing definite or probable usual interstitial pneumonia pattern, or surgical lung biopsy consistent with UIP
- Extent of fibrotic changes greater than emphysema on CT scan
- Able to take oral medication and adhere to the study regimen
- Ability to use video conferencing tools like CS-Link, Zoom, or Doximity for virtual visits
- Ability to complete pulmonary function tests and six-minute walk tests every 12 weeks per standard care
- Ability to complete high-resolution CT scans at baseline and 24 weeks per standard care
- Willingness to participate in home blood draws and travel to a local Quest Diagnostics lab
- Residency in California, Arizona, Georgia, Louisiana, Minnesota, or Oregon
You will not qualify if you...
- Forced vital capacity less than 40% predicted or diffusing capacity less than 30% predicted within 3 months of screening
- Evidence of other causes of interstitial lung disease such as connective tissue disease or hypersensitivity pneumonitis
- Other lung diseases including asthma, tuberculosis, sarcoidosis, or chronic infections
- Any unresolved acute illness or fever within 14 days before screening or first visit
- Use of tobacco products within the last 3 months or unwillingness to abstain during the study
- Participation in other investigational drug studies within 30 days prior to screening
- Any condition that would affect study data interpretation or participant safety
- Comorbid conditions likely to cause death within one year
- Inability to complete reliable pulmonary function tests
- Expected lung transplant within first 12 weeks of study
- Use of other IPF-directed therapies beyond standard care, including recent start of pirfenidone or nintedanib
- Use of cytotoxic, immunosuppressive, or cytokine modulating therapies recently
- Chronic prednisone use over 10 mg daily
- Use of medications with significant interactions with zinc
- Uncontrolled fluid buildup requiring frequent drainage
- Recent significant heart disease or unstable heart conditions
- Recent major surgery or planned surgery during the study
- History of active cancer within 5 years except certain localized cancers
- Prior stem cell or organ transplantation
- Any other disease or condition contraindicating investigational drug use or study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cedars-Sinai
Los Angeles, California, United States, 90048
Actively Recruiting
Research Team
S
Study Coordinator
CONTACT
T
Tanzira Zaman, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here